Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience

Nonparametric Estimation from Incomplete Observations

Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,232 · see citing works

Regression Models and Life-Tables

Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793 · see citing works

Nonparametric Estimation from Incomplete Observations

Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158 · see citing works

Regression Models and Life-Tables

Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297 · see citing works

Evaluation of survival data and two new rank order statistics arising in its consideration.

Mantel, N. (1966) · PubMed · Cited by 7,516 · see citing works

Note on the Sampling Error of the Difference Between Correlated Proportions or Percentages

McNemar, Q. (1947) · Psychometrika · doi:10.1007/bf02295996 · Cited by 4,754 · see citing works

Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril

Fraker, P. J., & Speck, J. C. (1978) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(78)91322-0 · Cited by 4,588 · see citing works

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

McLaughlin, P. J., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence‐Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,752 · see citing works

Characterization of a human B lymphocyte-specific antigen.

Stashenko, P., Nadler, L. M., Hardy, R., & Schlossman, S. F. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.4.1678 · Cited by 1,076 · see citing works

High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Philip, T. O., Armitage, J. O., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J.-Y. Y., Colombat, P., Goldstone, A. H., Gorin, N. C., Flesh, M., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706113162401 · Cited by 771 · see citing works

Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.

Beau, M. M. L., Albain, K. S., Larson, R. A., Vardiman, J., Davis, E. M., Blough, R. R., Golomb, H. M., & Rowley, J. D. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.3.325 · Cited by 668 · see citing works

Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support

Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310213291702 · Cited by 644 · see citing works

CD20: a regulator of cell-cycle progression of B lymphocytes

Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 598 · see citing works

Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies

Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 572 · see citing works

Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody

Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290703 · Cited by 547 · see citing works

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas

Press, O. W., Appelbaum, F. R., Martin, P. J., Matthews, D. C., Bernstein, I. D., Eary, J. F., Nelp, W. B., Gooley, T., Glenn, S., Porter, B. A., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92225-3 · Cited by 426 · see citing works

Follicular lymphoma: prognostic factors for response and survival.

Gallagher, C., Gregory, W. M., Jones, A. E., Stansfeld, A. G., Richards, M., Dhaliwal, H. S., Malpas, J. S., & Lister, T. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1470 · Cited by 424 · see citing works

A clinical trial of anti-idiotype therapy for B cell malignancy

Meeker, T. C., Lowder, J. N., Maloney, D. G., Miller, R., Thielemans, K., Warnke, R. A., & Levy, R. (1985) · Blood · doi:10.1182/blood.v65.6.1349.bloodjournal6561349 · Cited by 416 · see citing works

Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.

Nadler, L. M., Stashenko, P., Hardy, R., Kaplan, W. D., Button, L. N., Kufe, D. W., Antman, K. H., & Schlossman, S. F. (1980) · PubMed · Cited by 413 · see citing works

Natural history of and therapy for the indolent non-Hodgkin's lymphomas.

Horning, S. (1993) · PubMed · Cited by 399 · see citing works

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.1974 · Cited by 396 · see citing works

Treatment of Non-Hodgkin's Lymphoma

Wood, A. J. J., & Armitage, J. O. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281409 · Cited by 381 · see citing works

Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas

Press, O. W., Appelbaum, F. R., Ledbetter, J. A., Martin, P., Zarling, J. M., Kidd, P. G., & Thomas, E. D. (1987) · Blood · doi:10.1182/blood.v69.2.584.584 · Cited by 361 · see citing works

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype

Dyer, M. J. S., Hale, G., Hayhoe, F. G. J., & Waldmann, H. (1989) · Blood · doi:10.1182/blood.v73.6.1431.1431 · Cited by 349 · see citing works

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

Knox, S. J., Goris, M. L., Trisler, K. D., Negrin, R. S., Davis, T., Liles, T. M., Grillo-López, A. J., Chinn, P. C., Varns, C., Ning, S., et al. (1996) · PubMed · Cited by 327 · see citing works

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.

Liu, S. Y., Eary, J. F., Petersdorf, S. H., Martin, P. J., Maloney, D. G., Appelbaum, F. R., Matthews, D. C., Bush, S. A., Durack, L. D., Fisher, D. R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3270 · Cited by 285 · see citing works

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.

Einfeld, D. A., BROWN, J. P., Valentine, M. A., Clark, E. A., & Ledbetter, J. A. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02867.x · Cited by 277 · see citing works

Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.

Press, O. W., Farr, A. G., Borroz, K. I., Anderson, S. K., & Martin, P. J. (1989) · PubMed · Cited by 248 · see citing works

Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation.

Appelbaum, F. R., Sullivan, K. M., Buckner, C. D., Clift, R., Deeg, H. J., Fefer, A., Hill, R. S., Mortimer, J. E., NEIMAN, P. E., & Sanders, J. E. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.9.1340 · Cited by 233 · see citing works

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.

Goldenberg, D. M., Horowitz, J. A., Sharkey, R. M., Hall, T. C., Murthy, S., Goldenberg, H., Lee, R. E., Stein, R., Siegel, J. A., & Izon, D. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.548 · Cited by 199 · see citing works

Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study.

Rosen, S. T., Zimmer, A., Goldman-Leikin, R. E., Gordon, L. I., Kazikiewicz, J. M., Kaplan, E. H., Variakojis, D., Marder, R. J., Dykewicz, M. S., & Piergies, A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.4.562 · Cited by 180 · see citing works

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

DeNardo, G. L., DeNardo, S. J., Goldstein, D. S., Kroger, L. A., Lamborn, K. R., Lévy, N., McGahan, J. P., Salako, Q. A., Shen, S., & Lewis, J. P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3246 · Cited by 180 · see citing works

Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon

Brown, S. L., Miller, R., Horning, S. J., Czerwinski, D. K., Hart, S. M., McElderry, R., Basham, T. Y., Warnke, R. A., Merigan, T. C., & Levy, R. (1989) · Blood · doi:10.1182/blood.v73.3.651.651 · Cited by 174 · see citing works

Retention of B-cell-specific monoclonal antibodies by human lymphoma cells

Press, O. W., Howell-Clark, J., Anderson, S., & Bernstein, I. (1994) · Blood · doi:10.1182/blood.v83.5.1390.1390 · Cited by 171 · see citing works

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.

Kaminski, M. S., Fig, L. M., Zasadny, K. R., Koral, K. F., Delrosario, R., Francis, I. R., Hanson, C. A., Normolle, D. P., Mudgett, E. E., & Liu, C. P. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1696 · Cited by 152 · see citing works

Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes

Tedder, T. F., Forsgren, A., Boyd, A., Nadler, L. M., & Schlossman, S. F. (1986) · European Journal of Immunology · doi:10.1002/eji.1830160802 · Cited by 142 · see citing works

Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation.

Wahl, R. L., Kroll, S. M., & Zasadny, K. R. (1998) · PubMed · Cited by 117 · see citing works

Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.

Juweid, M. E., Sharkey, R. M., Markowitz, A., Behr, T. M., Swayne, L. C., Dunn, R. M., Hansen, H. J., Shevitz, J., Leung, S., & Rubin, A. (1995) · PubMed · Cited by 111 · see citing works

Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1.

DeNardo, G. L., DeNardo, S. J., O'Grady, L. F., Lévy, N., Adams, G. P., & Mills, S. L. (1990) · PubMed · Cited by 110 · see citing works

The Comparison of Survival Curves

Armitage, P. (1959) · Journal of the Royal Statistical Society Series A (General) · doi:10.2307/2342794 · Cited by 88 · see citing works

Untitled work

(1998) · PubMed · Cited by 87 · see citing works

Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.

Buchsbaum, D. J., Wahl, R. L., Normolle, D. P., & Kaminski, M. S. (1992) · PubMed · Cited by 84 · see citing works

Kettering award lecture. The role of marrow transplantation in the eradication of malignant disease

Thomas, E. D. (1982) · Cancer · doi:10.1002/1097-0142(19820515)49:10 · Cited by 72 · see citing works

Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.

Czuczman, M. S., Straus, D. J., Divgi, C. R., Graham, M. C., Garin‐Chesa, P., Finn, R., Myers, J., Old, L. J., Larson, S. M., & Scheinberg, D. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.2021 · Cited by 68 · see citing works

Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti- idiotype monoclonal antibodies

White, C. A., Halpern, S. E., Parker, B. A., Miller, R., Hupf, H. B., Shawler, D. L., Collins, H., & Royston, I. (1996) · Blood · doi:10.1182/blood.v87.9.3640.bloodjournal8793640 · Cited by 67 · see citing works

Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants

Mariani, G., Lasku, A., Balza, E., Gaggero, B., Motta, C., Luca, L. D., Dorcaratto, A., Viale, G. A., Neri, D., & Zardi, L. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971215)80:12+ · Cited by 53 · see citing works

Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy.

Ja, S. (1998) · PubMed · Cited by 43 · see citing works

Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation.

Wahl, R. L., Wissing, J. R., Rosario, R. D., & Zasadny, K. R. (1990) · PubMed · Cited by 39 · see citing works

A Phase I Escalating-Dose Safety, Dosimetry and Efficacy Study of Radiolabeled Monoclonal Antibody LYM-1

Kuzel, T., Rosen, S. T., Zimmer, A., Silverstein, E. A., SPIES, S. M., Saletan, S., Norvitch, M. E., Birkhofer, M. J., Shochat, D., LoBuglio, A. F., et al. (1993) · Cancer Biotherapy · doi:10.1089/cbr.1993.8.3 · Cited by 30 · see citing works

Bladder Cancer after Chemotherapy for Non-Hodgkin's Lymphoma

Travis, L. B., Curtis, R. E., Boice, J. D., & Fraumeni, J. F. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908243210815 · Cited by 28 · see citing works

High-dose therapy and transplantation in non-Hodgkin's lymphoma.

Morrison, V. A., & Peterson, B. A. (1999) · PubMed · Cited by 17 · see citing works

Protein Therapeutics: A Summary and Pharmacological Classification

Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 1,913 · see citing works

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,317 · see citing works

Monoclonal antibodies: versatile platforms for cancer immunotherapy

Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,282 · see citing works

Monoclonal antibody therapy of cancer

Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,254 · see citing works

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C. E., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,171 · see citing works

131 I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma

Kaminski, M. S., Tuck, M. K., Estes, J. M., Kolstad, A., Ross, C. W., Zasadny, K. R., Regan, D. D., Kison, P. V., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 715 · see citing works

Immunotherapy: past, present and future

Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 623 · see citing works

Follicular B helper T cells in antibody responses and autoimmunity

Vinuesa, C. G., Tangye, S. G., Moser, B., & Mackay, C. R. (2005) · Nature reviews. Immunology · doi:10.1038/nri1714 · Cited by 628 · see citing works

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M. N., Leonard, J. P., Fehrenbacher, L., Lister, T. A., Stagg, R., Tidmarsh, G. F., Kroll, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3918 · Cited by 585 · see citing works

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Forstpointner, R. (2004) · Blood · doi:10.1182/blood-2004-04-1323 · Cited by 579 · see citing works

Targeted α particle immunotherapy for myeloid leukemia

Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472 · see citing works

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 435 · see citing works

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Witzig, T. E., Vose, J. M., Zinzani, P. L., Reeder, C. B., Buckstein, R. J., Polikoff, J. A., Bouabdallah, R., Haïoun, C., Tilly, H., Guo, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq626 · Cited by 392 · see citing works

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390 · see citing works

New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma

Fisher, R. I., LeBlanc, M. L., Press, O. W., Maloney, D. G., Unger, J. M., & Miller, T. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1674 · Cited by 375 · see citing works

Brentuximab Vedotin (SGN-35)

Katz, J. B., Janik, J. E., & Younes, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0488 · Cited by 368 · see citing works

Non-Hodgkin Lymphoma: Diagnosis and Treatment

Ansell, S. M., & Armitage, J. O. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1087 · Cited by 356 · see citing works

Radiotheranostics: a roadmap for future development

Herrmann, K., Schwaiger, M., Lewis, J. S., Solomon, S. B., McNeil, B. J., Baumann, M. A., Gambhir, S. S., Hricak, H., & Weissleder, R. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30821-6 · Cited by 332 · see citing works

Targeted therapy of cancer with radiolabeled antibodies.

Goldenberg, D. M. (2002) · PubMed · Cited by 318 · see citing works

Monoclonal antibodies for cancer immunotherapy

Weiner, L. M., Dhodapkar, M. V., & Ferrone, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60251-8 · Cited by 305 · see citing works

Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911

Press, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P., LeBlanc, M. L., & Fisher, R. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8198 · Cited by 280 · see citing works

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

Anthony, L. B., Woltering, E. A., Espenan, G. D., Cronin, M. D., Maloney, T. J., & McCarthy, K. E. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31769 · Cited by 277 · see citing works

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Wiseman, G. A., Gordon, L. I., Multani, P. S., Witzig, T. E., SPIES, S. M., Bartlett, N. L., Schilder, R. J., Murray, J. L., Saleh, M. N., Allen, R. S., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4336 · Cited by 265 · see citing works

Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab

Horning, S. J., Younes, A., Jain, V. K., Kroll, S., Lucas, J. B., Podoloff, D. A., & Goris, M. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.040 · Cited by 259 · see citing works

Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin’s Lymphomas

Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D., Vose, J. M., Leonard, J. P., Kroll, S., Goldsmith, S. J., & Coleman, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.9217 · Cited by 240 · see citing works

Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma Patients

Armitage, J. O., Carbone, P. P., Connors, J. M., Levine, A. M., Bennett, J. M., & Kroll, S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.113 · Cited by 224 · see citing works

Future cancer research priorities in the USA: a Lancet Oncology Commission

Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S. N., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 211 · see citing works

Perspectives on cancer therapy with radiolabeled monoclonal antibodies.

Sharkey, R. M., & Goldenberg, D. M. (2005) · PubMed · Cited by 200 · see citing works

Transformation of Indolent B-Cell Lymphomas

Montoto, S., & Fitzgibbon, J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7577 · Cited by 190 · see citing works

Binding to CD20 by Anti-B1 Antibody or F(ab') 2 is sufficient for induction of apoptosis in B-cell lines

Cardarelli, P. M. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-001-0247-1 · Cited by 189 · see citing works

Radioimmunotherapy of non-Hodgkin lymphomas

Cheson, B. D. (2002) · Blood · doi:10.1182/blood-2002-06-1793 · Cited by 182 · see citing works

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

Press, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P., LeBlanc, M. L., Gaynor, E. R., Rivkin, S. E., & Fisher, R. I. (2003) · Blood · doi:10.1182/blood-2003-01-0287 · Cited by 173 · see citing works

Cancer radioimmunotherapy with alpha-emitting nuclides

Couturier, O., Supiot, S., Mougin‐Degraef, M., Faivre-Chauvet, A., Carlier, T., Chatal, J., Davodeau, F., & Chérel, M. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1803-2 · Cited by 169 · see citing works

Cancer Immunotherapy

Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 156 · see citing works

Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma

Leonard, J. P., Coleman, M., Kostakoğlu, L., Chadburn, A., Cesarman, E., Furman, R. R., Schuster, M. W., Niesvizky, R., Muss, D., Fiore, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.803 · Cited by 156 · see citing works

Diffuse large cell lymphoma

Coiffier, B. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200109000-00003 · Cited by 154 · see citing works

Diffuse large cell lymphoma

Cuneo, A., & Gl, C. (2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/37624 · Cited by 152 · see citing works

Trial Watch: Monoclonal antibodies in cancer therapy

Galluzzi, L., Vacchelli, E., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zucman‐Rossi, J., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17938 · Cited by 150 · see citing works

A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts

Press, O. W., Corcoran, M. C., Subbiah, K., Hamlin, D. K., Wilbur, D. S., Johnson, T., Theodore, L. J., Yau, E. K. C., Mallett, R. W., Meyer, D. L., et al. (2001) · Blood · doi:10.1182/blood.v98.8.2535 · Cited by 148 · see citing works

Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer

Tagawa, S. T., Beltran, H., Vallabhajosula, S., Goldsmith, S. J., Osborne, J. R., Matulich, D., Petrillo, K., Parmar, S., Nanus, D. M., & Bander, N. H. (2010) · Cancer · doi:10.1002/cncr.24795 · Cited by 142 · see citing works

Cancer Radioimmunotherapy

Sharkey, R. M., & Goldenberg, D. M. (2011) · Immunotherapy · doi:10.2217/imt.10.114 · Cited by 136 · see citing works

Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

Vallabhajosula, S., Kuji, I., Hamacher, K. A., Konishi, S., Kostakoğlu, L., Kothari, P. A., Milowsky, M. I., Nanus, D. M., Bander, N. H., & Goldsmith, S. J. (2005) · PubMed · Cited by 129 · see citing works

Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy

Cornelissen, B. T., & Vallis, K. A. (2010) · Current Drug Discovery Technologies · doi:10.2174/157016310793360657 · Cited by 124 · see citing works

Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.

Sgouros, G., Squeri, S., Ballangrud, Å., Kolbert, K. S., Teitcher, J. B., Panageas, K. S., Finn, R. D., Divgi, C. R., Larson, S. M., & Zelenetz, A. D. (2003) · PubMed · Cited by 119 · see citing works

Radiolabeled peptides in the diagnosis and therapy of oncological diseases

Weiner, R. E., & Thakur, M. L. (2002) · Applied Radiation and Isotopes · doi:10.1016/s0969-8043(02)00192-6 · Cited by 118 · see citing works

Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format

Shahied, L., Tang, Y., Alpaugh, R. K., Somer, R. A., Greenspon, D., & Weiner, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407888200 · Cited by 117 · see citing works

Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma

Dillman, R. O. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.126 · Cited by 115 · see citing works

Trial Watch

Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Fridman, W. H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27297 · Cited by 113 · see citing works

High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma

Morschhauser, F., Kraeber‐Bodéré, F., Wegener, W. A., Harousseau, J., Petillon, M., Huglo, D. G., Trümper, L. H. P., Meller, J., Pfreundschuh, M. G., Kirsch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7863 · Cited by 114 · see citing works

Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial

Zinzani, P. L., Pellegrini, C., Gandolfi, L., Stefoni, V., Quirini, F., Derenzini, E., Broccoli, A., Argnani, L., Pileri, S. A., & Baccarani, M. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.02.001 · Cited by 114 · see citing works

Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab

Lindén, O., Hindorf, C., Cavallin-Ståhl, E. K., Wegener, W. A., Goldenberg, D. M., Horne, H. B., Ohlsson, T. G., Stenberg, L., Strand, S., & Tennvall, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0172 · Cited by 114 · see citing works

Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.

Börjesson, P. K. E., Postema, E. J., Roos, J. C., Colnot, D. R., Marres, H. A. M., van Schie, M. H., Stehle, G., de Bree, R., Snow, G. B., Oyen, W. J. G., et al. (2003) · PubMed · Cited by 113 · see citing works

Advancing role of radiolabeled antibodies in the therapy of cancer

Goldenberg, D. M. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0348-5 · Cited by 110 · see citing works

Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.

Juweid, M. E. (2002) · PubMed · Cited by 110 · see citing works

Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin’s Lymphoma

Davies, A. J., Rohatiner, A. Z. S., Howell, S. J., Britton, K. E., Owens, S. E., Micallef, I. N., Deakin, D. P., Carrington, B. M., Lawrance, J., Vinnicombe, S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.055 · Cited by 109 · see citing works

Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry

Houghton, J. L., Membreno, R., Abdel-Atti, D., Cunanan, K. M., Carlin, S., Scholz, W. W., ZANZONICO, P. B., Lewis, J. S., & Zeglis, B. M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0503 · Cited by 108 · see citing works

Tailoring antibodies for radionuclide delivery

Kenanova, V. E., & Wu, A. M. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.1.53 · Cited by 105 · see citing works

Radiolabeled Peptides in Oncology

Weiner, R. E., & Thakur, M. L. (2005) · BioDrugs · doi:10.2165/00063030-200519030-00002 · Cited by 105 · see citing works

Human antibodies as next generation therapeutics

van Dijk, M. A., & van de Winkel, J. G. J. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00216-7 · Cited by 105 · see citing works

Targeted Radionuclide Therapy

Ersahin, D., Doddamane, I., & Cheng, D. (2011) · Cancers · doi:10.3390/cancers3043838 · Cited by 104 · see citing works

Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice

Jacene, H. A., Filice, R. W., Kasecamp, W., & Wahl, R. L. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.043489 · Cited by 102 · see citing works

Immunotherapy of Non-Hodgkin's Lymphomas

Press, O. W., Leonard, J. P., Coiffier, B., Levy, R., & Timmerman, J. M. (2001) · Hematology · doi:10.1182/asheducation-2001.1.221 · Cited by 102 · see citing works

Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas

Pagel, J. M., Hedin, N., Subbiah, K., Meyer, D. L., Mallet, R. W., Axworthy, D. B., Theodore, L. J., Wilbur, D. S., Matthews, D. C., & Press, O. W. (2003) · Blood · doi:10.1182/blood-2002-03-0874 · Cited by 101 · see citing works

Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256).

Kobayashi, H., Shirakawa, K., Kawamoto, S., Saga, T., Sato, N., Hiraga, A., Watanabe, I., Heike, Y., Togashi, K., Konishi, J., et al. (2002) · PubMed · Cited by 99 · see citing works

Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns

Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95 · see citing works

The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy

Goldenberg, D. M. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00108-1 · Cited by 95 · see citing works

Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab

Kaminski, M. S., Radford, J. A., Gregory, S. A., Leonard, J. P., Knox, S. J., Kroll, S., & Wahl, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0892 · Cited by 95 · see citing works

Neurologic complications of cancer therapy

Plotkin, S. R., & Wen, P. Y. (2003) · Neurologic Clinics · doi:10.1016/s0733-8619(02)00034-8 · Cited by 94 · see citing works

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

Davies, A. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210378 · Cited by 94 · see citing works

Multicenter Phase II Clinical Study of Iodine-131–Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma

Leahy, M. F., Seymour, J. F., Hicks, R. J., & Turner, J. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3470 · Cited by 93 · see citing works

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Sharkey, R. M., Brenner, A. J., Burton, J., Hajjar, G., Toder, S. P., Alavi, A. A., Matthies, A., Tsai, D. E., Schuster, S. J., Stadtmauer, E. A., et al. (2003) · PubMed · Cited by 92 · see citing works

Trial Watch

Vacchelli, E., Vitale, I., Tartour, É., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25595 · Cited by 91 · see citing works

Trial watch

Vacchelli, E., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22789 · Cited by 91 · see citing works

PET/CT Imaging and Radioimmunotherapy of Prostate Cancer

Bouchelouche, K., Tagawa, S. T., Goldsmith, S. J., Türkbey, B., Capala, J., & Choyke, P. L. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2010.08.005 · Cited by 90 · see citing works

A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections

Seyfizadeh, N., Seyfizadeh, N., Hasenkamp, J., & Huerta‐Yépez, S. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.09.001 · Cited by 89 · see citing works

Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

Illidge, T., Bayne, M., Brown, N. S., Chilton, S., Cragg, M. S., Glennie, M. J., Du, Y., Lewington, V. J., Smart, J., Thom, J., et al. (2008) · Blood · doi:10.1182/blood-2008-08-175653 · Cited by 88 · see citing works

Next generation radiotheranostics promoting precision medicine

Pomykala, K. L., Hadaschik, B. A., Sartor, O. A., Gillessen, S., Sweeney, C. J., Maughan, T., Hofman, M. S., & Herrmann, K. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.03.001 · Cited by 82 · see citing works

Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives

Hiddemann, W., Buske, C., Dreyling, M. H., Weigert, O., Lenz, G., Forstpointner, R., Nickenig, C., & Unterhalt, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.019 · Cited by 82 · see citing works

Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma

Brouwers, A. H., Mulders, P., Mulder, P. H. M. D., van den Broek, W. J. M., Buijs, W. C. A. M., Mala, C., Joosten, F. B. M., Oosterwijk, E., Boerman, O. C., Corstens, F. H. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.732 · Cited by 82 · see citing works

Trial Watch

Vacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27048 · Cited by 81 · see citing works

Advances in pretargeting biotechnology

Goodwin, D. A., & Meares, C. F. (2001) · Biotechnology Advances · doi:10.1016/s0734-9750(01)00065-9 · Cited by 81 · see citing works

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

Griffiths, G. L., Govindan, S. V., Sharkey, R. M., Fisher, D. R., & Goldenberg, D. M. (2003) · PubMed · Cited by 81 · see citing works

Targeted radionuclide therapy

Williams, L. E., DeNardo, G. L., & Meredith, R. F. (2008) · Medical Physics · doi:10.1118/1.2938520 · Cited by 80 · see citing works

Approved monoclonal antibodies for cancer therapy

Boyiadzis, M. M., & Foon, K. A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1151 · Cited by 80 · see citing works

Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate

Dahle, J., Borrebæk, J., Jónasdóttir, T. J., Hjelmerud, A. K., Melhus, K. B., Bruland, Ø. S., Press, O. W., & Larsen, R. H. (2007) · Blood · doi:10.1182/blood-2007-01-066803 · Cited by 80 · see citing works

Prostate-Specific Membrane Antigen-Based Therapeutics

Akhtar, N. H., Pail, O., Saran, A., Tyrell, L., & Tagawa, S. T. (2011) · Advances in Urology · doi:10.1155/2012/973820 · Cited by 79 · see citing works

Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations

Coulson, A., Levy, A., & Gossell‐Williams, M. (2014) · West Indian Medical Journal · doi:10.7727/wimj.2013.241 · Cited by 78 · see citing works

Bexxar®: Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma

Vose, J. M. (2004) · The Oncologist · doi:10.1634/theoncologist.9-2-160 · Cited by 76 · see citing works

Radiolabeled Antibodies for Cancer Imaging and Therapy

Barbet, J., Bardiès, M., Bourgeois, M., Chatal, J., Chérel, M., Davodeau, F., Faivre-Chauvet, A., Gestin, J., & Kraeber‐Bodéré, F. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-974-7_38 · Cited by 76 · see citing works

Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer

Weiner, L. M. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2209 · Cited by 74 · see citing works

Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)

Leonard, J. P., & Link, B. K. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30149 · Cited by 74 · see citing works

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Park, S. I., Shenoi, J., Pagel, J. M., Hamlin, D. K., Wilbur, D. S., Orgun, N. N., Kenoyer, A. L., Frayo, S. L., Axtman, A., Bäck, T. A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282327 · Cited by 73 · see citing works

Safety, biodistribution, pharmacokinetics, and immunogenicity of 99m Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck

Colnot, D. R., Roos, J. C., de Bree, R., Wilhelm, A. J., Kummer, J. A., Hanft, G., Heider, K., Stehle, G., Snow, G. B., & van Dongen, G. A. M. S. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0396-5 · Cited by 72 · see citing works

Rituximab: perspective on single agent experience, and future directions in combination trials

McLaughlin, P. J. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00130-5 · Cited by 72 · see citing works

Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients

Leahy, M. F., & Turner, J. H. (2010) · Blood · doi:10.1182/blood-2010-02-269753 · Cited by 71 · see citing works

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma

Gordon, L. I., Witzig, T. E., Wiseman, G., Flinn, I. W., Spies, S., Silverman, D. H. S., Emmanuolides, C., Cripe, L. D., Saleh, M. N., Czuczman, M. S., et al. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30148 · Cited by 70 · see citing works

Radiolabeled peptides in diagnosis and therapy

Weiner, R. E., & Thakur, M. L. (2001) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2001.27045 · Cited by 68 · see citing works

Tumor Immunotargeting Using Innovative Radionuclides

Kraeber‐Bodéré, F., Rousseau, C., Bodet‐Milin, C., Mathieu, C., Guérard, F., Frampas, É., Carlier, T., Chouin, N., Haddad, F., Chatal, J., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16023932 · Cited by 67 · see citing works

Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.

Subbiah, K., Hamlin, D. K., Pagel, J. M., Wilbur, D. S., Meyer, D. L., Axworthy, D. B., Mallett, R. W., Theodore, L. J., Stayton, P. S., & Press, O. W. (2003) · PubMed · Cited by 67 · see citing works

Intensive therapies in follicular non-Hodgkin lymphomas

Hunault, M., Ifrah, N., & Solal‐Céligny, P. (2002) · Blood · doi:10.1182/blood.v100.4.1141.h81602001141_1141_1152 · Cited by 65 · see citing works

A clinical and scientific overview of tositumomab and iodine I 131 tositumomab

Zelenetz, A. D. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70054-2 · Cited by 51 · see citing works

Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Vose, J. M., Wahl, R. L., Saleh, M. N., Rohatiner, A. Z. S., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R., & Kaminski, M. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1316 · Cited by 360 · see citing works

Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.

Wahl, R. L. (2005) · PubMed · Cited by 64 · see citing works

Duration of remission using I-131 tositumomab in patients with B-cell lymphoma relapsing after autologous stem cell transplant.

Shepard, D. D., Estes, J. M., Griffith, K. A., & Kaminski, M. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8071

Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma

Vose, J. M., Bierman, P. J., Enke, C. A., Hankins, J. H., Bociek, G. R., Lynch, J. C., & Armitage, J. O. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.117 · Cited by 160 · see citing works